VNRX VOLITIONRX LTD

MIXED Impact: 6/10 8-K
Horizon days Filed Mar 31, 2026 Processed 2mo ago SEC 0001477932-26-001830
earnings-rerun-backfill
Latest settled — T+20d
VNRX ▼ -34.00% at T+20d
NEUTRAL call ✗ call lost -34.00% · α vs SPY -43.72% · entry $4.00 → $2.64
Next anchor: T+60d in 11d
Last close $1.38 (close Jun 12) · -65.50% from $4.00 entry
Entry anchored
Mar 31, 03:59 PM ET
via Databento tick
T+1d
-14.25%
call -14.25% · α -14.33%
$3.43
settled 3mo ago
T+5d
-13.80%
call -13.80% · α -17.57%
$3.45
settled 2mo ago
T+20d
-34.00%
call -34.00% · α -43.72%
$2.64
settled 7w ago
T+60d
call — · α —
in 11d

Price Chart

Loading chart...

Executive Summary

VolitionRx reported full-year 2025 revenue of $1.7M (40% YoY growth) and Q4 revenue growth of 133%, but posted a net loss with EPS of -$0.05, missing consensus of -$0.04. The company highlighted progress in licensing discussions and secured $8.3M in post-year-end funding, though its auditor issued a going concern warning.

Actionable Insight

Despite strong revenue growth and cost reductions, the EPS miss and going concern warning may pressure shares short-term. Monitor the upcoming conference call for clarity on funding runway and licensing deal progress, which could provide upside catalysts.

Key Facts

  • Full-year 2025 revenue was $1.7M, up 40% from 2024
  • Q4 2025 revenue grew 133% YoY
  • Net loss for the year was down 14% vs 2024
  • Net cash used in operating activities was $19.7M, down 24%
  • Subsequent to year-end, raised $8.3M in non-dilutive and equity funding
  • Auditor's opinion includes going concern uncertainty
  • EPS of -$0.05 missed consensus of -$0.04 by 25%

Financial Impact

EPS miss of -$0.01 (25% worse than expected) on revenue of $1.7M (40% above prior year)

epsrevenueoperating_expensescash_flow

Risk Factors

  • Going concern qualification in auditor's report raises solvency concerns
  • Persistent losses and cash burn despite revenue growth
  • Reliance on future financing to sustain operations

Market Snapshot

Exchange
NYSE
Sector
In Vitro & In Vivo Diagnostic Substances

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001477932-26-001830
Document: vnrx_ex991.htm0001477932-26-001830
Document: 0001477932-26-001830-index-headers.html0001477932-26-001830
Document: 0001477932-26-001830-index.html0001477932-26-001830
Document: 0001477932-26-001830.txt0001477932-26-001830
8-K Data (Synthetic)0001477932-26-001830
9 reports for VNRX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VNRX — sortable, filterable
Type Now
Jun 9, 2026
5d ago
424B5
BEARISH ★ 7/10
$1.38 awaiting T+5awaiting T+5$1.38 (+0.00%)
Jun 5, 2026
9d ago
424B5
BEARISH ★ 6/10
$1.79 awaiting T+5awaiting T+5$1.38 (+22.91%)
May 22, 2026
23d ago
8-K
BEARISH ★ 7/10
$2.94 $2.32▲ +21.09%▲ +22.30%$1.38 (+53.06%)
May 14, 2026
4w ago
8-K
NEUTRAL ★ 4/10
$2.00 $3.13▲ +56.50%▲ +55.54%$1.38 (−31.00%)
Apr 30, 2026
6w ago
10-K/A
NEUTRAL ★ 2/10
$2.43 $2.25▼ −7.41%▼ −9.75%$1.38 (−43.21%)
Apr 28, 2026
6w ago
8-K
NEUTRAL ★ 3/10
$2.64 $2.49▼ −5.68%▼ −8.79%$1.38 (−47.73%)
Apr 23, 2026
7w ago
8-K
BEARISH ★ 8/10
$2.80 $2.64▲ +5.71%▲ +7.19%$1.38 (+50.71%)
Apr 17, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$3.20 $2.72▼ −14.88%▼ −15.79%$1.38 (−56.88%)
Mar 31, 2026
10w ago
8-K
MIXED ★ 6/10
$4.00 $3.45▼ −13.80%▼ −17.57%$1.38 (−65.50%)
Showing 9 of 9

US Market Status

Market Closed — Opens in 5h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access